Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions.

ABSTRACT: Cognitive impairment risk in Parkinson's disease increases with disease progression and poses a significant burden to the patients, their families and society. There are no disease-modifying therapies or preventative measures for Parkinson's disease mild cognitive impairment (PD-MCI), or Parkinson's disease dementia (PDD). This article reviews current and previously investigated treatments and those under investigation, including pharmacologic, non-pharmacologic and surgical procedures. There are currently no effective pharmacologic or non-pharmacologic treatments for PD-MCI. The only recommended treatment for PDD currently is rivastigmine, a cholinesterase inhibitor. Donepezil and galantamine-other cholinesterase inhibitors-are possibly useful. Memantine, a N-methyl-D-aspartate (NMDA) rec

SUBMITTER: Sun C 

PROVIDER: S-EPMC8073727 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature